Adoptive cell therapy in acute myeloid leukemia: the current landscape and emerging strategies DOI
Serena Tharakan, Douglas Tremblay, Jacques Azzi

и другие.

Leukemia & lymphoma/Leukemia and lymphoma, Год журнала: 2024, Номер unknown, С. 1 - 14

Опубликована: Окт. 25, 2024

Efforts to produce adoptive cell therapies in AML have been largely unfruitful, despite the success seen lymphoid malignancies. Identifying targetable antigens on leukemic cells that are absent normal progenitor remains a major obstacle, as is hostile tumor microenvironment created by blasts. In this review, we summarize challenges development of such CAR-T, CAR-NK, and TCR-T AML, discussing both autologous allogeneic therapies. We also discuss methods address myelotoxicity associated with these therapies, including rapidly switchable CAR platforms CRISPR-Cas9 genetic engineering hematopoietic stem cells. Finally, present current clinical landscape areas, along future directions field.

Язык: Английский

In vitro cancer cell line luminescence‐based validation of anticancer phytocompounds obtained from Leucas biflora against HELA cervical and A549 lung cancer cells DOI

K. Chitra,

Muthusamy Sureshkumar,

Aiswarya Muraleedharan

и другие.

Luminescence, Год журнала: 2024, Номер 39(8)

Опубликована: Авг. 1, 2024

Abstract Current research aims to screen the anticancer prospective of Leucas biflora phytocompounds against apoptotic regulator target protein essential for cancer progression. In gas chromatography–mass spectrometry analysis major such as tetracosahexaene, squalene, phytol, 22‐stigmasten‐3‐one, stigmasterol, fluorene, and 1,4‐dihydro were identified in ethanolic leaf extract . vitro, free radical scavenging potential was examined through its DPPH ABTS IC 50 value 15.35 13.20 μg/ml, respectively. Dose‐dependent cytotoxicity monitored both A549 lung HELA cervical cells. highly reduces cell viability cells vitro assays. produces 23.76% 29.76% rates lines, their values differ slightly at 95.80 90.40 molecular docking protein–ligand complex 5Y9T‐16132746 showed a maximum score −14 kcal/mol by exhibiting stable binding affinity interactions among all screened complexes. Based on nine from two reference standard drugs chosen further analysis. Further validation reveals that possess good ADMET, Bioactivity density functional theory indices.

Язык: Английский

Процитировано

6
Tonic signaling in CAR-T therapy: the lever long enough to move the planet DOI
Yuwei Huang, Haopeng Wang

Frontiers of Medicine, Год журнала: 2025, Номер unknown

Опубликована: Март 21, 2025

Язык: Английский

Процитировано

0
Hidden Partner of Immunity: Microbiome as an Innovative Companion in Immunotherapy DOI Open Access

P. Kim,

Sook-Haeng Joe, Heeyoung Kim

и другие.

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(2), С. 856 - 856

Опубликована: Янв. 20, 2025

Recent studies have highlighted that the microbiome is essential factor can modulate clinical activity of immunotherapy. However, role varies significantly across different immunotherapies, suggesting it critical to understand precise function in each type While many previous primarily focus on summarizing immune checkpoint inhibitors, we seek explore a novel aspect other immunotherapies such as mesenchymal stem cell therapy, chimeric antigen receptor T and antibodies-based therapy (e.g., adalimumab, infliximab, bevacizumab, denosumab, etc.) which are rarely summarized reviews. Moreover, highlight innovative strategies for utilizing microbial metabolites enhance response Collectively, believe our manuscript will provide insights approaches researchers, could drive development next generation personalized therapeutic interventions using microbiomes.

Язык: Английский

Процитировано

0
Conversion of anti-tissue factor antibody sequences to chimeric antigen receptor and bi-specific T-cell engager format DOI Creative Commons
Sarah C. Saunderson, Joshua Colin Halpin,

G. M. Y. Tan

и другие.

Cancer Immunology Immunotherapy, Год журнала: 2024, Номер 73(10)

Опубликована: Авг. 6, 2024

The efficacy of antibody-targeted therapy solid cancers is limited by the lack consistent tumour-associated antigen expression. However, antigens shared with non-malignant cells may still be targeted using conditionally activated-antibodies, or chimeric receptor (CAR) T CAR NK activated either tumour microenvironment following 'unlocking' via multiple antigen-recognition. In this study, we have focused on tissue factor (TF; CD142), a type I membrane protein present range tumours as basis for future development conditionally-activated BiTE cells. TF frequently upregulated providing selective advantage growth, immune evasion and metastasis, well contributing to pathology thrombosis extrinsic coagulation pathway.

Язык: Английский

Процитировано

1
Pre-Clinical Models for CAR T-Cell Therapy for Glioma DOI Creative Commons
Gust Vandecandelaere, Rishab Ramapriyan,

Matthew A. Gaffey

и другие.

Cells, Год журнала: 2024, Номер 13(17), С. 1480 - 1480

Опубликована: Сен. 4, 2024

Immunotherapy represents a transformative shift in cancer treatment. Among myriad immune-based approaches, chimeric antigen receptor (CAR) T-cell therapy has shown promising results treating hematological malignancies. Despite aggressive treatment options, the prognosis for patients with malignant brain tumors remains poor. Research leveraging CAR surged recent years. Pre-clinical models are crucial evaluating safety and efficacy of these therapies before they advance to clinical trials. However, current recapitulate human tumor environment varying degrees. Novel vitro vivo techniques offer opportunity validate but also have limitations. By strengths weaknesses various pre-clinical glioma models, this review aims provide roadmap development testing tumors.

Язык: Английский

Процитировано

0
Conversion of anti-tissue factor antibody sequences to chimeric antigen receptor and bi- specific T cell engager format DOI Creative Commons

Saunderson SC,

Joshua Colin Halpin,

Grace Min Yi Tan

и другие.

Research Square (Research Square), Год журнала: 2024, Номер unknown

Опубликована: Июнь 20, 2024

Abstract Background The efficacy of antibody-targeted therapy solid cancers is limited by the lack consistent tumour-associated antigen expression. However, tumour associated antigens shared with non-malignant cells may still be targeted using conditionally activated-antibodies or chimeric receptor (CAR) T CAR NK activated either microenvironment following 'unlocking' via multiple antigen-recognition. In this study we have focused on tissue factor (TF; CD142), a type I membrane protein present range tumours as basis for future development conditionally-activated BiTE cells. TF frequently upregulated providing selective advantage growth, immune evasion and metastasis, well contributing to pathology thrombosis extrinsic coagulation pathway. Methods Two well-characterised anti-TF monoclonal antibodies hATR-5 TF8-5G9 maintained their nanomolar affinities conversion into single chain (scFv) format. format.CD28-CD3-based CD3-based format based mAb scFv constructs were able activate CD28-CD3-based Conclusion Because broad expression cancers, antibody formats provide useful addition biologics cellular-based therapy.

Язык: Английский

Процитировано

0
Adoptive cell therapy in acute myeloid leukemia: the current landscape and emerging strategies DOI
Serena Tharakan, Douglas Tremblay, Jacques Azzi

и другие.

Leukemia & lymphoma/Leukemia and lymphoma, Год журнала: 2024, Номер unknown, С. 1 - 14

Опубликована: Окт. 25, 2024

Efforts to produce adoptive cell therapies in AML have been largely unfruitful, despite the success seen lymphoid malignancies. Identifying targetable antigens on leukemic cells that are absent normal progenitor remains a major obstacle, as is hostile tumor microenvironment created by blasts. In this review, we summarize challenges development of such CAR-T, CAR-NK, and TCR-T AML, discussing both autologous allogeneic therapies. We also discuss methods address myelotoxicity associated with these therapies, including rapidly switchable CAR platforms CRISPR-Cas9 genetic engineering hematopoietic stem cells. Finally, present current clinical landscape areas, along future directions field.

Язык: Английский

Процитировано

0